Pentavalent Meningococcal Conjugate vaccine

EuBiologics aims to develop an affordable pentavalent meningococcal vaccine (NmCV-5) to provide broad protection against invasive meningococcal disease. A Phase I trial in South Korea demonstrated strong immunogenicity and safety, with responses comparable to or better than existing vaccines. Meningococcal epidemics threaten the Sub-Saharan African Meningitis Belt, and while a first pentavalent vaccine has been prequalified, Gavi support for non-emergency use will not begin until late 2025. EuBiologics aims to become the second supplier of a WHO PQ NmCV-5 by 2027, ensuring a secure supply and competitive pricing. In a previous RIGHT Foundation grant, EuBiologics and PATH conducted a Phase I trial in South Korea. Based on the results, Phase II cohorts will be enrolled, and interim safety and immunogenicity data will be used to guide the subsequent enrollment of Phase III cohorts in younger age groups. Phase II cohorts will be enrolled, and interim safety and immunogenicity data will inform subsequent enrollment in Phase III cohorts in younger age groups.